NCT02606630View on ClinicalTrials.gov

[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Multiple Sclerosis
Interventions
DRUG

ABT-555

ABT-555 will be administered on Visit 4 in Part 2 only

Trial Locations (2)

SW17 ORE

Site Reference ID/Investigator# 141463, London

E1 2AT

Site Reference ID/Investigator# 141461, Whitechapel

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY